Objective: During the menopausal transition, total testosterone (T) remains unchanged, whereas estrogen decreases markedly, creating a state of relative androgen excess. We hypothesized that change in the T-to-estradiol (T/E 2 ) ratio during the menopausal transition would be associated with incident metabolic syndrome.
I t has long been the belief that estrogen deficiency during the menopausal transition was responsible for the increased risk of cardiovascular disease seen in postmenopausal women. However, prospective randomized clinical trails have not demonstrated cardiovascular disease protection from estrogen therapy, 1<3 calling this long-standing hypothesis into question. Less attention has been paid to the role of endogenous androgens on cardiovascular risk factors in women despite studies suggesting that androgens may play an important role. High testosterone (T) levels predict insulin resistance and incident type 2 diabetes in postmenopausal women. 4 Increased T and low sex hormoneYbinding globulin (SHBG) levels have also been individually linked to the some of the components of metabolic syndrome (MS) and diabetes in both premenopausal and postmenopausal women. 5<11 A low SHBG level has been demonstrated to be independently associated with MS in postmenopausal women, after adjustment for body mass index (BMI), in a recent sample from the Women's Health Study. 12 During the menopausal transition, T levels remain unchanged, whereas estradiol (E 2 ) levels decrease. Thus, the T/E 2 ratio at baseline increases over time, creating a state of Brelative androgen excess.[ 13<15 The relative androgen excess created during the menopausal transition may help explain the increasing risk of cardiovascular disease in postmenopausal women.
MS generates a greater sensitivity for the detection of cardiovascular disease than its individual constituents. 16<19 We hypothesized that the relative excess of androgens created during the menopausal transition would be associated with an increased risk of developing MS. We used the prospective data for the first 5 years of follow-up of the 3,302 premenopausal and early perimenopausal women enrolled in the Study of Women's Health Across the Nation (SWAN), a multicenter, multiethnic, community-based, longitudinal study of perimenopausal women, to test this hypothesis.
METHODS

Study population
The design, sampling strategy, cohort recruitment, and enrollment of SWAN have been described in detail elsewhere. 20 In brief, participants were enrolled at seven clinical sites. Recruitment techniques were designed to generate a community-based sample of women at each of the seven sites. All seven sites enrolled white women, and each site also enrolled women belonging to one prespecified minority ethnic group. African American women were enrolled in Boston, MA, Chicago, IL, the Detroit, MI area, and Pittsburgh, PA. Japanese, Chinese, and Hispanic women were enrolled in Los Angeles, CA, Oakland, CA, and Hudson County, NJ, respectively. Eligibility criteria for entry into the SWAN longitudinal cohort were as follows: age between 42 and 52 years, the presence of a uterus and at least one ovary, no current use of estrogens or other medications known to affect ovarian function, at least one menstrual period in the 3 months before screening, and self-identification as a member of one of the five eligible ethnic groups. The institutional review board at each SWAN center approved the study. All women provided written informed consent before participation in the study.
A total of 3,302 women were enrolled. At baseline, the cohort consisted of 1,550 white, 935 African American, 281 Japanese, 250 Chinese, and 286 Hispanic women. Women were followed yearly. The data reported here represent the analysis of the first 5 years of follow-up. From the full SWAN cohort, a total of 1,862 women were used for these analyses and 1,440 women were excluded from the analysis for the presence of the following confounders: presence of MS or diabetes at entry (n = 844), abnormal thyroid-stimulating hormone (0.1-9.99 KIU/mL; n = 65) or T (9100 ng/mL; n = 73) level at any single visit or use of hormone therapy or surgical menopause (n = 239). Remaining exclusions were for missing or incomplete follow-up data (n = 219).
Questionnaires and physical measurements
Demographic information, history of hypertension or diabetes, smoking status, perceived stress, physical activity, race/origin, and menopause status were obtained using standardized questionnaires. Primary race/ethnicity was selfdefined as one of the five groups noted above. Nutrient intake for total fat consumption and percentage of total calories consumed from fat per day were assessed using the National Cancer Institute (Block) food frequency questionnaire, which was enhanced to accommodate the ethnic diversity in SWAN. 21 Information on alcohol consumption was derived from the food frequency questionnaire and categorized based on amount of alcohol consumption. 22 Standardized protocols were used to measure height, weight, waist circumference, and blood pressure.
Biochemical measurements and calculation of relative androgen excess
Biochemical analyses were done on the samples obtained at baseline and years 1, 3, and 5 of follow-up. Blood was drawn on days 2 to 5 of the follicular phase after an 8-hour fast. Lipids and glucose were assayed at the Medical Research Laboratories (Lexington, KY), which is certified by the National Heart Lung and Blood Institute, Centers for Disease Control and Prevention Part III program. Lipid and lipoprotein fractions were analyzed on EDTA-treated plasma. Total cholesterol and triglyceride levels were analyzed by enzymatic methods. High-density lipoprotein (HDL) cholesterol was isolated using heparin-2 M manganese chloride. Serum insulin was measured using the radioimmunoassay (DPC Coat-A-Count, Diagnostics Products Corp, Los Angeles, CA) procedure and monitored monthly as part of the quality assurance program by the Diabetes Diagnostic Laboratory at the University of Missouri. Glucose was measured using a hexokinase-coupled reaction (Boehringer Mannheim Diagnostics, Indianapolis, IN).
Hormone assays were conducted at the University of Michigan SWAN Endocrine Laboratory using the ACS-180 automated analyzer (Bayer Diagnostics Corp, Norwood, MA). SHBG was measured using a newly developed, twosite chemiluminescent assay with a lower limit of detection (LLD) of 2 nmol/L; intra-assay and interassay coefficients of variation (CVs) were 9.9% and 6.1%, respectively. The E 2 assay modifies the rabbit anti-E2-6 ACS-180 immunoassay to increase sensitivity, with an LLD of 1.0 pg/mL; intra-assay and interassay CVs were 10.6% and 6.4%, respectively. The T assay modifies the rabbit polyclonal anti-T ACS-180 immunoassay, with an LLD of 2.19 ng/dL; intra-assay and interassay CVs were 10.5% and 8.5%, respectively.
Calculation of free androgen index, T/E 2 molar ratio, and relative androgen excess
The free androgen index (FAI) was used to estimate the amount of free T, as it correlates well with the free T level as measured by equilibrium dialysis [FAI = 100 Â T (ng/mL)/ 28.84 Â SHBG (nmol/L)]. 23 The free estrogen index (FEI) was calculated as 100 Â E 2 (pg/mL)/272.11 Â SHBG (nmol/L).
To quantify the amount of T relative to E 2 , the molar ratio of log(FAI/FEI) was used. The log(FAI/FEI) is equivalent to the molar ratio of log(T/E 2 ) as SHBG is represented in both the numerator and denominator and thus cancels out of the equation 
Definition of MS
Currently, there is no uniform well-accepted definition for MS. We used the American Heart Association/National Heart Blood and Lung Institutes definition for MS because the ethnic diversity of our study population included Asians, a group at increased risk of diabetes associated hypertension and dyslipidemia at lower overall adiposity. 24<27 Any participant with any three of the following five criteria was considered to have MS: (1) waist circumference of 88 cm or greater (Q80 cm for Asians), (2) triglyceride level of 150 md/dL or greater, (3) HDL level of less than 50 mg/dL, (4 ) systolic blood pressure of 130 mm Hg or greater or diastolic blood pressure of 85 mm Hg or greater or receiving antihypertensive drug treatment, and (5) fasting blood glucose level of 100 mg/dL or greater.
Statistical methods
Ethnic differences in baseline characteristics were tested using a standard W 2 test or one-way analyses of variance. Where necessary, variables were log-transformed. To assess how hormones changed over time, the unadjusted means of T, E 2 , T/E 2 , and RAE were plotted against time. In addition, change over time was estimated using mixed models, with each hormone modeled as a simple function of time, adjusting for baseline age. Incidence rates of MS were calculated as the total number of cases divided by the total number of person-years of follow-up. A univariate complimentary log-log model was used to test for ethnic differences in MS incidence.
The association between incident MS and hormone levels was modeled using a discrete-time proportional hazards model, that is, a complementary log-log model. 28, 29 A discrete-time model instead of a Cox analysis was used because our identification of incident MS cases occurs only at several discrete times (ie, visits 1, 3, and 5), which is known as grouped or interval-censored data. In each model, incident MS was modeled as a function of baseline (log-transformed) hormone and average annual change in hormone levels between baseline and each follow-up visit (on a log scale). All models were adjusted for ethnicity, clinical site, age at baseline, a time interval indicator, and Bphlebotomy in window[ (whether phlebotomy at each visit was in days 2-5 of the menstrual cycle).
The residual BMI, a term designed to capture departure from expected change in BMI, was added into the models to correct for difference in weight over time because waist circumference is included in the definition of MS. This latter variable was calculated as the error term from a simple model of each follow-up BMI as a function of baseline BMI. All other covariates, including physical activity, level of education, alcohol consumption, smoking, total fat consumption, percentage of total calories consumed from fat per day, income, and perceived stress, were taken from the baseline visit and included in final models only where statistical significance was achieved. Analysis was carried out using SAS version 8. Model fit was verified using the Hosmer and Lemeshow goodness-of-fit test. 30 The primary reason for participant dropout was the initiation of hormone therapy. The validity of all models was assessed by investigating the impact of hormone therapy users on model results.
RESULTS
The baseline characteristics of the final analytic sample are shown in Table 1 . The distributions of all variables differed very significantly across ethnic groups (P G 0.01-P G 0.001), except for marginally significant betweenYethnic group differences for SHBG (P = 0.04) and FAI (P = 0.06). The T/E 2 molar ratio did not differ significantly by ethnic group. Overall, Hispanics were considerably more likely to be less well educated. Chinese and Japanese women were more likely to be premenopausal at baseline. Chinese women were also considerably less likely to smoke and drink alcohol and consumed a lower percentage of total calories from fat, whereas whites were more likely to be physically active. The components of MS, E 2 , and T differed across ethnic groups. No differences were seen in SHBG, FAI, and T/E 2 molar ratio across ethnic groups.
During the follow-up period, the age-adjusted E 2 levels decreased by an estimated 12.0% each year (P G 0.0001), whereas the average annual age-adjusted decrease in total T was much less (3.1% per year, P G 0.0001, Fig. 1 ). At baseline, the unadjusted median T/E 2 molar ratio ranged from 5.62 in Hispanics to 6.62 in Chinese women ( Table 1) . The age-adjusted T/E 2 molar ratio increased 10.1% per year during the 5 years of follow-up (P G 0.001), creating a state of androgen excess relative to the baseline T/E 2 values (Fig. 2 ).
There were 257 new cases of MS during the 6,296 personyears of follow-up. Hispanic women had a greater incidence rate than white women did (8.81 vs 4.12 per 100 personyears), whereas Chinese women had lower rates than white women did (2.34 vs 4.12 per 100 person-years) ( Table 2) .
Individual models were created to asses the association of E 2 (model 1), T (model 2), SHBG (model 3), FAI (model 4), and the T/E 2 molar ratio, RAE (model 5) with the incidence of MS (Table 3 ). Neither the baseline E 2 nor its rate of change was associated with incidence (model 1). Although higher baseline T and FAI and lower SHBG levels were associated with higher incidence, the models for rates of change over time were not statistically significant (models 2-4). Unlike FAI and SHBG, both a higher baseline T/E 2 molar ratio and change over time in the RAE were associated with increased risk of developing MS (model 5).
The associations between risk of MS and either baseline T/E 2 molar ratio and RAE did not vary significantly by ethnicity, with coefficients similar in magnitude and direction across all ethnic groups. Interaction terms between ethnicity and baseline hormone levels, ethnicity and change in hor-mone levels, and baseline hormone and change in hormone were not found to be significant.
To estimate for potential changes in risk associated with hormone therapy use, each model was rerun including hormone therapy users and adjusted for hormone therapy use via an indicator variable. The model coefficients for each hormone and its change were unchanged in direction and significance level when the indicator variable was placed in the model. The indicator variable for hormone therapy use was not significant, suggesting that hormone therapy use was not associated with risk of MS.
DISCUSSION
Higher baseline T/E 2 ratio and change over time in RAE were associated with increased risk of developing MS during the menopausal transition. Neither baseline E 2 nor its decline over time was associated with increased overall risk. Although the baseline T, FAI, and SHBG all appeared to be associated with an increased risk of developing MS, their change over time was not. These findings suggest that there is a complex interaction between T and E 2 , rather than simply changes in T, FAI, and SHBG, determining a woman's risk of developing MS during the menopausal transition.
Our results highlight the fact that estrogen deficiency by itself is not as important as the relationship between T and E 2 during the menopausal transition. This finding is supported by primary and secondary prevention randomized, clinical trials of postmenopausal women that did not demonstrate a benefit of exogenous E 2 . 1<3 Observational cohort studies have demonstrated that increased endogenous E 2 in postmenopause is not associated with reduced cardiovascular events. 4 Endogenous and exogenous T influences a woman's cardiovascular risk factors. Unbound circulating T best reflects a woman's overall androgen status. 31 High FAI levels have been associated with a more atherogenic lipid profile independent of metabolic factors and health behaviors. 5 High FAI levels have been associated with MS in postmenopausal women. 6 Administration of T to normal women and female transsexuals leads to insulin resistance as measured by an insulin clamp. 32, 33 Such doses are typically supraphysiological for women, and at lower doses of T, carbohydrate metabolism has been reported to be unaffected in two short-term studies of more than 1,000 women, although specific measures were not shown and long-term data are not available. 34, 35 We have previously demonstrated that high FAI and low SHBG levels were strongly and consistently related to adverse cardiovascular risk factors during a cross-sectional analysis of the SWAN cohort. Even after adjusting for body mass index, FAI was most strongly associated with plasminogen activator inhibitor-I, tissue plasminogen activator, triglycerides, and glucose, whereas SHBG was most strongly associated with plasminogen activator inhibitor-I, triglycerides, and HDL. 36, 37 The present findings extend the logic of examining androgens in women in a longitudinal fashion because they appear to be strongly associated with adverse intermediate outcomes such as MS.
The Prospective Cardiovascular Munster Program was used to estimate the risk of an acute coronary event in the Melbourne Women's Midlife Health Project, a cohort of 438 Australian midlife women who were followed through the menopausal transition. 38 In this study, lower-than-average E 2 levels, E 2 levels that decreased, and high free T levels were associated with increased risk of a coronary event. Although our study supports the increased risk seen with FAI, neither our study nor other previous studies support their findings as they pertain to decreasing estrogen levels. 4<6 During our prospective analysis, both the FAI and SHBG at baseline were associated with an increased risk of developing MS, but their change over time was not. This suggests that the baseline values in FAI and SHBG predict a woman's overall risk independent of the change over time in these variables and is in agreement with previously published data from SWAN, in which the baseline characteristics of the women were associated with the presence of MS. In this study, SHBG and FAI remained independently associated with MS at baseline after adjusting for other factors such as age and waist circumference. Thus, although circulating free androgens and SHBG may predict a woman's risk before she enters the menopausal transition, the change in these two factors over time does not explain why a woman's risk of developing MS increases during the menopausal transition. In our cohort, the T/E 2 molar ratio increased over time, creating a state of RAE during the menopausal transition (Fig. 2 ). Both the baseline T/E 2 molar ratio and the change over time in the RAE were associated with increased risk of developing MS after correcting for multiple confounding variables. The associated risk seen with RAE was independent of ethnicity, notwithstanding the ethnic differences in the baseline values of E 2 , T, and incidence of MS across the ethnic groups, suggesting that ethnicity may predict an individual woman's overall risk 39 but not the manner in which her risk changes during the transition.
Thus, the baseline T/E 2 molar ratio and its change over time suggest that the complex interplay between both T and E 2 during the menopausal transition may be responsible for increasing the risk of MS. Physiological interplay between androgens and estrogens, which typically have opposing actions, in various endocrine targets is well established. 40 Androgen and estrogen responses occur at the promoter regions of selected genes independently through distinct response elements. This androgen-estrogen interplay may reflect the combined effects of sex steroidYspecific regulated gene expression; each hormone may affect the expression of the other's receptor, or each receptor may interact with another. 41<44 A potential mechanism that could explain our findings is the effect of androgens on insulin resistance. Exogenous administration of androgens to women has been demonstrated to increase insulin resistance. 31, 32 Because SHBG levels are suppressed by hyperinsulinemia, the RAE during the menopausal transition could lead to an insulin-resistant state that subsequently further suppresses levels of SHBG, causing higher levels of free T. Because low SHBG levels have been previously associated with an increased risk of a variety of cardiovascular risk factors and incident cardiovascular disease in postmenopausal women independent of insulin, obesity, and dyslipidemia, further study is needed to assess whether this proposed mechanism is valid. 45, 46 Our study has limitations. A small number of women in our cohort may have developed polycystic ovarian syndrome (PCOS) during follow-up. However, in the SWAN cohort, women with PCOS were largely excluded at entry as 87% of SWAN participants reported an intermenstrual interval of 21 to 35 days at baseline and the eligibility requirement of at least one menstrual period within the past 3 months. We also excluded from the analyses women with MS and diabetes at entry, further decreasing the presence of women who may have had PCOS in this analysis. It must also be kept in mind that our blood sampling was restricted to the early follicular phase of the cycle. During the early stages of the menopausal transition, E 2 and, to a lesser extent, T are secreted in varying quantities over the menstrual cycle, and thus, this single assessment may not be reflective of the entire hormone exposure.
CONCLUSIONS
Our results imply that the complex interplay between T and E 2 has been a relatively overlooked factor as a cause of morbidity in women at midlife. The current lack of evidence that exogenous estrogen decreases cardiovascular morbidity and mortality in postmenopausal women argues that there is not a simple, single hormone that influences cardiovascular disease risk in perimenopausal and postmenopausal women. An understanding of how changes in the T/E 2 molar ratio influence the ontogeny of MS and insulin resistance may be important for the development of new cardiovascular disease prevention strategies. Moreover, despite the recent enthusiasm for the use of T as a form of hormonal replacement for postmenopausal women, 30, 47 the possible introduction of an adverse metabolic profile in at least some women needs to be considered before its widespread initiation. 
